Furosemide — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Kidney Disease

• Amlodipine
• Atorvastatin
• Lisinopril
• Losartan

Also listed for Heart Failure

• Carvedilol
• Digoxin
• Metoprolol
• Spironolactone

Other medications in Heart & Cardiovascular

• Gemfibrozil
• Hydralazine
• Hydrochlorothiazide
• Icosapentaenoic Acid
• Iloprost
• Inclisiran
• Indapamide
• Irbesartan

What Furosemide is approved for (FDA label)

Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide Tablets are particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.

Source: Read the full FDA label on DailyMed. Label effective date: August 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Furosemide (FDA label)

Adverse reactions are categorized below by organ system and listed by decreasing severity.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Furosemide (FDA label)

Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Furosemide (FDA label)

WARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.

Source: FDA prescribing information (DailyMed). Set ID: dba00759-87b4-4ecf-998e-ba03ed3d2f1a. SPL document ID: 593ecae2-6f71-f39c-e063-6394a90abb6c. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.